AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Mar 24, 2025
30849_dirs_2025-03-24_8ed6a9fe-9dde-4c26-b23e-c39afc8beff6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-03-20
Reporting Person: German Christopher Paul (Corporate Controller & CAO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-20 | Common Stock | M | 1163 | — | Acquired | 3233 | Direct |
| 2025-03-21 | Common Stock | S | 344 | $54.23 | Disposed | 2889 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-20 | Restricted Stock Units | $ | M | 1163 | Disposed | Common Stock (1163) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.